Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Moving beyond GWAS and eQTL Analysis to Validated Hits in Chronic Kidney Disease

(2019) Janina Müller-Deile et al.   Cell Metabolism

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting

(2019) Ellen M. Langer et al.   Cell Reports

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

(2019) A. Capasso et al.   Journal for ImmunoTherapy of Cancer

Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.

(2019) Jerome Galon et al.   JOURNAL OF CLINICAL ONCOLOGY

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

Pathogenic Germline Variants in 10,389 Adult Cancers

(2018) Kuan-lin Huang et al.   CELL

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

(2018) Tina Cascone et al.   Cell Metabolism

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma

(2018) Douglas B. Johnson et al.   CLINICAL CANCER RESEARCH

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

(2018) Minan Wang et al.   FASEB JOURNAL

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

(2018) Jinyang Li et al.   IMMUNITY

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

(2018) Min Yuen Teo et al.   JOURNAL OF CLINICAL ONCOLOGY

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

(2018) Franck Pagès et al.   LANCET

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

(2018) Deng Pan et al.   SCIENCE

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

(2018) Diana Miao et al.   SCIENCE

Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy

(2018) Akihiro Hosoi et al.   Scientific Reports

A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity

(2018) Hilary Sherman et al.   Frontiers in Immunology

Immune oncology, immune responsiveness and the theory of everything

(2018) Tolga Turan et al.   Journal for ImmunoTherapy of Cancer

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Co-mutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade

(2018) Jie Wang et al.   CANCER RESEARCH

Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.

(2018) Vylyny Chat et al.   JOURNAL OF CLINICAL ONCOLOGY

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

(2018) Andrea Botticelli et al.   Journal of Translational Medicine

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

(2018) Amit V. Khera et al.   NATURE GENETICS

Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity

(2018) Aida Ferreiro-Iglesias et al.   Nature Communications

12PMSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies

(2018) J Galon et al.   ANNALS OF ONCOLOGY

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells

(2018) Oxana Ryabaya et al.   BIOMEDICINE & PHARMACOTHERAPY

Evolution of Metastases in Space and Time under Immune Selection

(2018) Mihaela Angelova et al.   CELL

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

(2018) Christof C. Smith et al.   JOURNAL OF CLINICAL INVESTIGATION

Quantifying Immunoscore performance – Authors' reply

(2018) Franck Pagès et al.   LANCET

Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration

(2018) Yoong Wearn Lim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

(2017) Leisha A. Emens et al.   EUROPEAN JOURNAL OF CANCER

Mutant IDH1 regulates the tumor-associated immune system in gliomas

(2017) Nduka M. Amankulor et al.   GENES & DEVELOPMENT

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

(2017) Qian Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?

(2017) Giuseppe Palmieri et al.   Journal of Translational Medicine

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus

(2017) Ji-Feng Feng et al.   MEDICINE

The era of GWAS is over – Yes

(2017) Koen Vandenbroeck   Multiple Sclerosis Journal

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

(2017) Whijae Roh et al.   Science Translational Medicine

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

(2017) Chan-Young Ock et al.   Nature Communications

Innate and adaptive immune traits are differentially affected by genetic and environmental factors

(2017) Massimo Mangino et al.   Nature Communications

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

(2017) Pornpimol Charoentong et al.   Cell Reports

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

(2017) Alexandra Snyder et al.   PLOS MEDICINE

The era of GWAS is over – Yes

(2017) Koen Vandenbroeck   Multiple Sclerosis Journal

A Blueprint to Advance Colorectal Cancer Immunotherapies

(2017) Dung T. Le et al.   Cancer Immunology Research

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

(2017) Wouter Hendrickx et al.   OncoImmunology

Predictive Value of FcR Polymorphisms

(2017) Riccardo Dolcetti   JAMA Oncology

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents

(2016) Sylvia Herter et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis

(2016) M. Vogelsang et al.   CLINICAL CANCER RESEARCH

Disentangling the relationship between tumor genetic programs and immune responsiveness

(2016) Davide Bedognetti et al.   CURRENT OPINION IN IMMUNOLOGY

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer

(2016) Stephen M Hatfield et al.   CURRENT OPINION IN PHARMACOLOGY

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

(2016) Y. Qin et al.   MOLECULAR CANCER THERAPEUTICS

Autoimmune diseases — connecting risk alleles with molecular traits of the immune system

(2016) Maria Gutierrez-Arcelus et al.   NATURE REVIEWS GENETICS

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy

(2016) Marka R. Crittenden et al.   Oncotarget

Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond

(2016) Cristina Migali et al.   Therapeutic Advances in Medical Oncology

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

(2016) Elise P. Salerno et al.   OncoImmunology

Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet

(2016) Elodie Viry et al.   Frontiers in Oncology

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences

(2015) Petter Brodin et al.   CELL

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Do human leukocyte antigen E polymorphisms influence graft-versus-leukemia after allogeneic hematopoietic stem cell transplantation?

(2015) Ehteramolsadat Hosseini et al.   EXPERIMENTAL HEMATOLOGY

Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer

(2015) Howard L. Kaufman   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition

(2015) Jennifer L. Leight et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

(2015) E. Vacchelli et al.   SCIENCE

How cell death shapes cancer

(2015) V Labi et al.   Cell Death & Disease

Consensus nomenclature for CD8+T cell phenotypes in cancer

(2015) Lionel Apetoh et al.   OncoImmunology

Tumor-intrinsic oncogene pathways mediating immune avoidance

(2015) Stefani Spranger et al.   OncoImmunology

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Development and function of human innate immune cells in a humanized mouse model

(2014) Anthony Rongvaux et al.   NATURE BIOTECHNOLOGY

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Beyond GWASs: Illuminating the Dark Road from Association to Function

(2013) Stacey L. Edwards et al.   AMERICAN JOURNAL OF HUMAN GENETICS

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

(2013) D Bedognetti et al.   BRITISH JOURNAL OF CANCER

Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study

(2013) P. Queirolo et al.   CANCER INVESTIGATION

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

(2013) Jérôme Galon et al.   IMMUNITY

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

(2013) Gabriela Bindea et al.   IMMUNITY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Overcoming Current Limitations in Humanized Mouse Research

(2013) Michael A. Brehm et al.   JOURNAL OF INFECTIOUS DISEASES

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

(2013) J. Baginska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Strange attractors: DAMPs and autophagy link tumor cell death and immunity

(2013) W Hou et al.   Cell Death & Disease

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia

(2012) Yuliya Pylayeva-Gupta et al.   CANCER CELL

IRF5 gene polymorphisms in melanoma

(2012) Lorenzo Uccellini et al.   Journal of Translational Medicine

A genetic inference on cancer immune responsiveness

(2012) Ena Wang et al.   OncoImmunology

Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling

(2011) Domenico Coppola et al.   AMERICAN JOURNAL OF PATHOLOGY

Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R null humanized mice

(2011) E. Billerbeck et al.   BLOOD

Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma

(2011) G. R. Weiss et al.   CLINICAL CANCER RESEARCH

New IBD genetics: common pathways with other diseases

(2011) C. W. Lees et al.   GUT

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon

(2010) Helen Gogas et al.   CANCER

FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis

(2010) Pauline Andreu et al.   CANCER CELL

Gene Signature in Melanoma Associated With Clinical Activity

(2010) Thomas F. Gajewski et al.   CANCER JOURNAL

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Fractionated Radiation Therapy Can Induce a Molecular Profile for Therapeutic Targeting

(2010) Molykutty John-Aryankalayil et al.   RADIATION RESEARCH

Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence

(2009) M. Camus et al.   CANCER RESEARCH

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

(2009) Theocharis Panaretakis et al.   EMBO JOURNAL

Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade

(2009) Willemijn B. Breunis et al.   JOURNAL OF IMMUNOTHERAPY

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

(2008) Lisa H Butterfield et al.   Journal of Translational Medicine

Tumour immunity: effector response to tumour and role of the microenvironment

(2008) Alberto Mantovani et al.   LANCET

The immunologic constant of rejection

(2008) Ena Wang et al.   TRENDS IN IMMUNOLOGY